WO2006040893A1 - 新規な抗菌性医薬 - Google Patents
新規な抗菌性医薬 Download PDFInfo
- Publication number
- WO2006040893A1 WO2006040893A1 PCT/JP2005/016611 JP2005016611W WO2006040893A1 WO 2006040893 A1 WO2006040893 A1 WO 2006040893A1 JP 2005016611 W JP2005016611 W JP 2005016611W WO 2006040893 A1 WO2006040893 A1 WO 2006040893A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- formula
- group
- antibacterial
- hydroxyethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to an antibacterial pharmaceutical comprising a combination of a ⁇ -latatam compound represented by the following formula [1] and powerful rubapenems.
- MRSA methicillin-resistant staphylococci
- MRCNS methicillin-resistant coredalase-negative staphylococci
- the inventors of the present invention have not only mutually complemented the antibacterial spectrum, but also carbapenem by using a combination of the compound represented by the following formula [1] and powerful rubapenems. It was found that the antibacterial activity was superior to that of existing agents by enhancing the antibacterial activity of the other species, and the present invention was completed.
- the present invention relates to an antibacterial drug comprising a combination of a j8-latatam compound represented by the following formula [1] and powerful rubapenems.
- R 1 is a lower alkyl group or a lower alkyl group substituted by a hydroxyl group
- R 2 is a hydrogen atom or a lower alkyl group
- X is 0, S or NH
- m and n are independent of each other. 0 to 4, and the sum of m and n is 0 to 4
- Y 1 is a halogen atom, a cyano group, an optionally protected hydroxyl group, an optionally protected amino group, a lower group
- 1 to 4 Y 1 may be present and 2 may be substituted on the same carbon atom.
- the present invention also provides the above antibacterial medicament, wherein in formula [1], X is S, and the sum of m and ⁇ is 2 or 3.
- the antibacterial drug wherein is 1 (R) hydroxyethyl
- R 1 is 1- (R) hydroxyethyl, R 2 methyl
- X The antibacterial medicine, wherein S is S, the sum of m and ⁇ is 2 or 3, ⁇ 1 is methyl or hydroxymethyl, and ⁇ 2 is a hydrogen atom,
- the j8-ratata compound represented by the formula [1] is (4R, 5S, 6S) — 6— [(1R) — 1 Hydroxyethyl] -4-methyl-3-( ⁇ 4 [(53) — 5-methyl-2 , 5-Dihydro-111-pyrrole — 3 yl] 1,3 thiazole 2 yl ⁇ sulfar) 7 oxo 1 azabicyclo [3.2.0] hepto 2 ene 2—the above-mentioned antibacterial drug, which is a strong rubonic acid,
- the antibacterial pharmaceutical dosage form is an injection, a vial! /, Is a kit for the above antibacterial pharmaceutical, for patients in need of treatment, the
- Bacterial infections comprising administering to a patient in need of treatment an effective amount of a combination of
- examples of the lower alkyl group include methyl, ethyl, ⁇ -propyl, isopropyl, ⁇ -butyl, isobutyl, tert-butyl. , N-pentyl or n-hexyl, or a straight chain or branched chain one having 1 to 6 carbon atoms.
- Examples of the lower alkyl group substituted by a hydroxyl group include those having 1 to 6 carbon atoms, such as hydroxymethyl, 1-hydroxyxetyl, 2-hydroxyethyl, 1-hydroxy 1-methylolethyl, 1-hydroxypropyl, and 2-hydroxypropyl. It is done.
- Examples of the lower alkyloxy group include linear or branched carbon atoms such as methoxy, ethoxy, n-propoxy, isopropoxy, n butoxy, isobutoxy, tert butoxy, n pentoxy or n-hexoxy. ⁇ 6 are listed.
- Examples of the lower alkylamino group include methylamino-containing ethylamino, n-propylamino-containing isopropylamino-containing n-butylamino, isobutylamino, tert-butylamino-containing n-pentylamino, n-hexylamino-containing methylethylamino-containing ketylamino, di-amino (n-Propyl) Ami di (isopropyl) Ami di (n-Butyl) Ami di (n-Pentyl) Ami di (n-Hexyl) Amino like linear or branched And an amino group having a mono- or di-substituted lower alkyl group having 1 to 6 carbon atoms.
- the halogen atom represents fluorine, chlorine, bromine or iodine.
- Examples of 5- to 7-membered heterocycles include 3,4 dihydro-2H pyrrole ring, 2,3,4,5-tetrahydropyridine ring, 3,4,5,6-tetrahydro-2H casee ring, and the like.
- Examples of the substituent of the optionally substituted lower alkyl group include a hydroxyl group, a lower alkyloxy group, a lower alkylthio group, a lower alkylsulfinyl group, a lower alkyl group, and the like.
- ⁇ 7-membered ring may be formed.
- — CONR 7 (where R 6 and R 7 have the same meaning as above), — NR 6a COR 7a (where R 6a and R 7a are independent of each other) Represents a hydrogen atom or a lower alkyl group.
- -OCONR 6 R 7 (where R 6 and R 7 are as defined above), -SO NR 6 R 7 (where R 6 and R 7 Is the same as above
- Examples of the lower alkyl carbonyl group include methyl carbo yl, ethyl carbo ol, n-propyl carbonyl, isopropyl carbonyl, n-butyl carbonyl, isoptino decano levonole, tert-butino decano levonole, n— Examples thereof include straight-chain or branched lower alkyl carbon groups having 2 to 7 carbon atoms such as pentinorecanolboninole or n-hexylcarbonyl.
- lower alkylcarboxoxy group examples include, for example, methylcarboxoxy, ethylcarbonyloxy, n-propylcarbonyloxy, isopropylcarbonyloxy, n-butylcarbonyloxy, isobutylcarbonyloxy, tert-butylcarboxyloxy.
- a linear or branched lower alkylcarbonyloxy group having 2 to 7 carbon atoms such as n-pentylcarbonyloxy or n-hexylcarbonyloxy.
- the lower alkyloxycarbonyl group includes, for example, methyloxycarbonyl, ethyloxycarbonyl, n-propyloxycarbonyl, isopropyloxycarbonyl, n-butyloxycarbonyl, isobutyloxy Carbonyl, tert-butyloxy force Examples thereof include straight-chain or branched lower alkyloxycarbonyl groups having 2 to 7 carbon atoms such as noreboninore, n-pentyloxycarbonyl or n-hexyloxycarbonyl.
- the lower alkyl moiety in the lower alkylthio group, lower alkylsulfinyl group and lower alkylsulfonyl group includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butynole, isobutyl, tertbutyl, n-pentyl or Examples include straight-chain or branched-chain ones having 1 to 6 carbon atoms such as n-hexyl.
- substituent of the optionally substituted strong rubamoyl group include one or two lower alkyl groups, or pyrrolidine, piperidine or azepane formed together with the nitrogen atom of the strong rubamoyl group. Etc.
- substituent of the amino group which may be substituted include, for example, pyrrolidine, piperidine or azepane formed together with one or two lower alkyl groups, or a nitrogen atom of an amino group. Is mentioned.
- Examples of the optionally substituted 5- to 7-membered heterocyclic substituent include a lower alkyl group, a hydroxyl group, a lower alkyloxy group, a lower alkylcarbonyl group, a lower alkylcarbo-loxy group, and a lower alkyloxycarbo group.
- a lower alkyl group a hydroxyl group, a lower alkyloxy group, a lower alkylcarbonyl group, a lower alkylcarbo-loxy group, and a lower alkyloxycarbo group.
- protective group for the carboxyl group various commonly used protective groups can be used, but preferably a linear or branched chain such as methyl, ethyl, isopropyl, tert butyl and having 1 to 5 carbon atoms.
- Lower alkyl groups for example, halogeno lower alkyl groups having 1 to 5 carbon atoms such as diiodinated acetyl, 2,2,2 trichloroethyl, for example 1 to 5 carbon atoms such as methoxymethyl, ethoxymethyl, and isobutoxymethyl
- a lower alkoxymethyl group such as, for example, a lower aliphatic asiloxymethyl group having 1 to 5 carbon atoms such as acetooxymethyl, propio-loxymethyl, butyryloxymethyl, pivaloyloxymethyl, for example, 1 such as 1 ethoxycarboxoxyl (C to C) Lower alkoxy carbo
- An oxetyl group for example, an aralkyl group such as benzyl, p-methoxybenzyl, o-trobenzyl, p-todobenzyl, a lower alkenyl group having 3 to 7 carbon atoms such as aryl, 3-methylallyl, a benzhydryl group, or A phthalidyl group is mentioned.
- the protecting group for the hydroxyl group and the protecting group for the amino group may be any of various commonly used protecting groups.
- the hydroxyl group-protecting group has 1 to 5 carbon atoms such as tert-butyloxycarbol.
- a lower alkoxycarbonyl group for example, a 2-5 halogenated alkoxycarbonyl group, such as allyloxycarbon, such as 2-iodinated oxycarbonyl, 2,2,2 trichloroethyl ether
- C3-C7 lower alkoxycarbol groups such as carbol, for example, benzoxycarbol, p-methoxy cypendinole, xikanoleboninole, o ditrobenginole Xyalkylenobonole, p aralkyloxycarbonyl groups such as ditroben dioxycarbonyl, eg trials such as trimethylsilyl, triethylsilyl, tert butyldimethylsilyl A kill silyl group is mentioned.
- Examples of 2 include methyl, and preferable R 1 includes 1- (R) -hydroxyethyl.
- the pharmaceutically acceptable salt of the ⁇ -ratata compound represented by the formula [1] is a commonly used non-toxic salt.
- examples of such salts include inorganic base salts such as sodium, potassium, calcium, magnesium and ammonium such as triethyl ammonium, pyridinium and diisopropyl ammonium as intramolecular carboxylic acid salts.
- Organic base salts such as -um, and intramolecular salts formed with positive charges such as quaternary ammonium ions on the 3rd-position side chain.
- Inorganic acid salts such as sulfuric acid and phosphoric acid, for example, organic acid salts such as formic acid, acetic acid, oxalic acid, methanesulfonic acid, and benzenesulfonic acid.
- Non-toxic esters of ⁇ -ratata compounds represented by the formula [1] include force rubapenem It means a conventional pharmaceutical acceptable substance at the carboxyl group at the 2-position of the antibacterial agent. For example, it is easily hydrolyzed in vivo such as acetooxymethyl, bivaluloyloxymethyl, 1 (ethoxycarbo-loxy) ethyl, and phthalidyl. Things.
- the ⁇ -ratata compound represented by the formula [1] or a pharmaceutically acceptable salt or non-toxic ester thereof may be an anhydride, hydrate or solvate thereof.
- optical isomers based on the 4th, 5th and 6th asymmetric carbons of the force rubapenem skeleton there are optical isomers based on the 4th, 5th and 6th asymmetric carbons of the force rubapenem skeleton, and these isomers are all represented by a single formula for convenience.
- the compounds used in the present invention include all isomers and isomer mixtures based on each asymmetric carbon atom.
- isomers based on substituent Upsilon 1 also exist, and are of Gobutsu used in the present invention includes all isomers and isomer mixtures.
- R 2 is a lower alkyl group
- the carbon atom at the 4-position has a (4R, 5S, 6S) coordination at the 5-position carbon atom 3 ⁇ 4-coordinate and the (4R, 5S, 6S) coordination, or (4R, 5S, 6R) ) Coordination compounds can be mentioned.
- R 1 -hydroxyethyl as shown in the above formula, there are R-coordination and S-coordination isomers at the 8-position as well, and R-coordination can be mentioned as a preferred one. .
- ⁇ -ratata compound represented by the formula [1] a pharmaceutically acceptable salt thereof, or a non-toxic ester thereof is known and can be produced by the method described in International Publication No. 02-38564. .
- ⁇ -ratata compounds represented by the formula [1] used in the present invention preferred compounds are listed below.
- One strength rubapenem used in the present invention is not particularly limited, but meropenem, imipenem, parpenem, biapenem, enoletapenem, dripenem (S — 4661), CS-023 or ME-1036.
- Gram negative bacteria including Pseudomonas aeruginosa Lubapenems having particularly strong activity, such as meropenem, imipenem, panipenem, biapenem, dripenem (S-4661), CS-023, particularly preferably meropenem. Name.
- Doripenem S-4661
- S-4661 is described in The Journal of Antibiotics Vol. 49, No. 2, 199-205, 1996 and JP-A-5-294970, and is a compound having the following structural formula:
- CS-023 is described in The Journal of Antibiotics Vol. 56, No. 6, 565-579, 2003, and is a compound having the following structural formula:
- ME-1036 is described in Antimicrobial Agents and Chemotherapy, Aug. 2004, 2381-2837 and WO 02Z42321, and is a compound having the following structural formula:
- the mixing ratio of the j8-latatam compound represented by the formula [1] and the powerful rubapenem is not particularly limited, and the optimal mixing ratio should be changed depending on the pharmacokinetic properties of each drug.
- the value of j8-latatam compound Z-force rubapenem in the body is 1Z 10 ⁇ : It is desirable to have a compounding ratio that can be maintained in the range of LO, especially j8 for meropenem —Lactam Compound Z Meropenem should have a blending ratio that can maintain the value of 1 to 4 as long as possible.
- Examples of dosage forms for using the combination preparation of the present invention as an antibacterial agent for treating bacterial infections include parenteral administration such as intravenous injection, intramuscular injection, infusion administration, rectal administration, and inhalation administration. It is done.
- the agent may contain other active ingredients required by the patient depending on the symptoms.
- the above-mentioned appropriate dosage form can be produced by a method known per se generally used in the pharmaceutical process, in which the active compound is mixed with an ordinary carrier, excipient, binder, stabilizer, etc. which are acceptable.
- injections e.g., subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, etc.
- the active ingredient dispersing agent e.g., Tween (Tw een) 80 (Atlas Powder Co., USA) , HCO 60 (manufactured by Nikko Chemicals), polyethylene glycol, carboxymethylcellulose, sodium alginate, etc.), preservatives (eg, methylparaben, pylparaben, benzyl alcohol, chlorobutanol, phenol), isotonic agents (eg, Aqueous solvents (e.g., distilled water, physiological saline, Ringer's solution, etc.) or oil solvents (e.g., olive oil,
- a solubilizer eg, sodium salicylate, sodium acetate, etc.
- a stabilizer eg, human serum albumin, etc.
- a soothing agent eg, benzalkonium chloride, pro-hydrochloride hydrochloride, etc.
- the antibacterial medicament comprising a combination of the ⁇ -ratata compound represented by the formula [1] of the present invention, a pharmaceutically acceptable salt thereof or a non-toxic ester thereof, and powerful rubapenems is further provided.
- these active ingredients can be administered parenterally, separately or simultaneously. If the active ingredient is formulated separately at this time, it can be mixed and administered using a diluent at the time of use, but it can be administered separately or with a time difference to the same subject. A little.
- the dosage of the antibacterial agent of the present invention varies depending on symptoms, age, body weight, dosage form, number of administrations, etc., but is usually the total amount of the active ingredients of the mixture of the present invention for adults. 100 mg to 12 g per day is administered once or divided into several times, preferably over several days. It can be reduced or increased as needed.
- the mixing ratio of the drug can be appropriately selected depending on the administration subject, the age and weight of the administration target, symptoms, administration time, dosage form, administration method, combination of drugs, and the like.
- Dissolve Compound 1 250 mg
- meropenem trihydrate 250 mg
- the solution is sterilized by aseptic filtration and filled into a nozzle to make a solution injection.
- Dissolve Compound 1 250 mg
- meropenem trihydrate 250 mg
- the solution is sterilized by aseptic filtration and filled into ampoules to make a solution injection.
- Dissolve compound 1 250 mg
- meropenem trihydrate 250 mg
- 50 ml of distilled water 50 ml
- the aqueous solution is sterilized by aseptic filtration and filled into vials.
- the filling solution is freeze-dried to obtain a freeze-dried preparation.
- nosocomial infection pathogenic bacteria 18 strains 27 strains (Staphylococcus aure us 3 teeth, Staphylococcus epiaermidis 1 teeth, Micrococcus luteus 1 teeth, Streptoco ecus pyogenes 1 strain, iinterococcus faecalis 1 strain, miterococcus faecium 1 tooth, Bacillus subtilis 1 Escherichia coli 3 1 Antibacterial activity against standard strains was measured for ia 1 strain, Enterobacter cloacae 1 strain, Citrobacter freundii 1 strain, Moraxella catar rhalis 2 strain).
- the sample-containing agar medium was inoculated. After culturing the agar medium at 37 ° C for about 20 hours, observe the presence or absence of bacterial growth, and set the minimum concentration of the sample to inhibit growth to MIC (minimum inhibitory concentration, ⁇ gz mi). [0057] 3) Method for preparing test drug
- each chemical solution was weighed and dissolved in distilled water to prepare each sample solution.
- the two types of sample solutions were mixed at various concentration ratios to obtain a mixture solution.
- this mixture solution was serially diluted with a 2-fold serial dilution.
- each sample solution was used as it was, and diluted serially in 2-fold serial dilution from the highest concentration to the lowest concentration.
- the FIC index was calculated based on these minimum concentrations.
- the FIC index is an evaluation standard generally used as a method for evaluating the combined effect of antibiotics (for example, described in The Japanese Journal of Antibiotics vol.58, pl68-178, 2005). In other words, if the FIC index determined by the following formula is 1 or less, it is considered that the combination with the concentration ratio has a medicinal effect enhancing effect. Also, if the FIC index exceeds 1, the combined efficacy enhancement effect is considered indefinite.
- FIC index (MIC with MICZA alone when combined with A) + (MIC with MICZB alone when combined with B)
- N. C. represents Not calculated.
- Tables 1-a to 1-d show the combined effect of meropenem and compound 1 on the above-mentioned standard strains. The test method and test drug preparation were performed as described above.
- Table 2-a and Table 2 show the combined effect of meropenem and Compound 1 on the above clinical isolates -b.
- the test method and the preparation of the test drug were performed as described above.
- MEPM or ME is meropenem
- SM is compound 1
- IPM is imipenem
- PAPM parpenem
- BIPM is biapenem
- DRPM is doripenem
- PIPC piperaciri CAZ stands for ceftazidime
- AZT stands for azreonam
- CPFX stands for ciprofloxacin.
- the numerical value in each table is the minimum concentration ( ⁇ g / ml) of each drug that has inhibited the growth of bacteria, and means the minimum concentration ( ⁇ g / ml) of the drug contained in the mixture.
- Str.pyogenes Cook ⁇ 0.016 ⁇ 0.008 ⁇ o.oie ⁇ 0.008 .G.
- S.aureus S94088 (hetero-MRSA) 4 0.25 0.25 0.25 1.1 ⁇
- S.aureus SP-7928 (homo-MRSA) 32 1 1 1 1.03 ⁇ ⁇ s3 ⁇ 4
- Str.pyogenes Cook ⁇ 0.016 .008 ⁇ 0.016 ⁇ 0.016 N.C.
- Str.pyogenes Cook ⁇ 0.016 0 * 008 ⁇ 0.016 ⁇ 0,063 N.C.
- Efaeca / is ATGC19433 4 1 0.25 3 1.1
- Str.pyogenes Cook ⁇ 0.002 0.004 ⁇ 0.002 ⁇ 0.002 N.C.
- M S. aureus SP-7928 (homo MRSA)> 32 1 2 2 ⁇ 2.16007 S, epi ermi ⁇ Ss IAM1296> 32 0.016 0.031 0.031 ⁇ 2.0
- Str.pyogenes Cook 16 ⁇ 0.002 0.004 0.004 N.C.
- M catarrhs / is ATCC25238 0.125 ⁇ 0.002 ⁇ 0.002 ⁇ 0.002 N.C.
- the combination of the present invention is effective as a prophylactic / therapeutic agent for various infectious diseases since it has a medicinal effect enhancing effect on various strains.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002581663A CA2581663A1 (en) | 2004-10-08 | 2005-09-09 | Novel antimicrobial medicament |
JP2006540852A JPWO2006040893A1 (ja) | 2004-10-08 | 2005-09-09 | 新規な抗菌性医薬 |
CN2005800344249A CN101039669B (zh) | 2004-10-08 | 2005-09-09 | 新的抗微生物药物 |
US11/664,810 US20090018111A1 (en) | 2004-10-08 | 2005-09-09 | Novel Antimicrobial Medicament |
EP05782332A EP1797879A4 (en) | 2004-10-08 | 2005-09-09 | NEW ANTIMICROBIAL MEDICAMENT |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004296349 | 2004-10-08 | ||
JP2004-296349 | 2004-10-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006040893A1 true WO2006040893A1 (ja) | 2006-04-20 |
Family
ID=36148195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/016611 WO2006040893A1 (ja) | 2004-10-08 | 2005-09-09 | 新規な抗菌性医薬 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20090018111A1 (ja) |
EP (1) | EP1797879A4 (ja) |
JP (1) | JPWO2006040893A1 (ja) |
KR (1) | KR20070061895A (ja) |
CN (1) | CN101039669B (ja) |
CA (1) | CA2581663A1 (ja) |
TW (1) | TW200621243A (ja) |
WO (1) | WO2006040893A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009075323A1 (ja) * | 2007-12-12 | 2009-06-18 | Dainippon Sumitomo Pharma Co., Ltd. | β-ラクタム化合物の安定形結晶 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006101062A1 (ja) * | 2005-03-22 | 2006-09-28 | Daiichi Sankyo Company, Limited | 1-アルキルピロリジン構造を有するカルバペネム誘導体の製造方法 |
RU2470715C1 (ru) * | 2011-07-21 | 2012-12-27 | Открытое акционерное общество "Алтай-кокс" | Центрифуга |
CN111840236B (zh) * | 2020-08-07 | 2022-09-02 | 安徽康正康仁药业有限公司 | 一种注射用美罗培南丙磺舒钠复方冻干制剂 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002038564A1 (en) * | 2000-11-08 | 2002-05-16 | Sumitomo Pharmaceuticals Company, Limited | NOVEL β-LACTAM COMPOUNDS AND PROECSS FOR PRODUCING THE SAME |
JP2002525275A (ja) * | 1998-09-01 | 2002-08-13 | メルク エンド カムパニー インコーポレーテッド | カルバペネム抗菌組成物および治療方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5492983A (en) * | 1977-12-29 | 1979-07-23 | Sanraku Inc | Antibiotics ps-4 and ps-7 |
JPS5781498A (en) * | 1980-11-11 | 1982-05-21 | Meiji Seika Kaisha Ltd | New antibiotic sf-2103a substance and its preparation |
JPS5852222A (ja) * | 1981-09-24 | 1983-03-28 | Meiji Seika Kaisha Ltd | 抗菌剤組成物 |
JPH0347122A (ja) * | 1989-02-21 | 1991-02-28 | Banyu Pharmaceut Co Ltd | 抗菌性組成物 |
JPH02250829A (ja) * | 1989-03-24 | 1990-10-08 | Fujisawa Pharmaceut Co Ltd | 抗菌剤 |
JPH02279627A (ja) * | 1989-04-19 | 1990-11-15 | Sumitomo Pharmaceut Co Ltd | 抗菌組成物 |
US5068232A (en) * | 1990-04-10 | 1991-11-26 | American Cyanamid Company | Novel 2-substituted alkyl-3-carboxy carbapenems as antibiotics and a method of producing them |
JPH0429930A (ja) * | 1990-05-24 | 1992-01-31 | Fujisawa Pharmaceut Co Ltd | エンテロコッカス属細菌感染症の予防または治療用抗菌剤 |
US5317016A (en) * | 1991-08-20 | 1994-05-31 | Shionogi Seiyaku Kabushiki Kaisha | Pyrrolidylthiocarbapenem derivative |
US5741782A (en) * | 1996-03-29 | 1998-04-21 | Cryolife, Inc. | Antibiotic cocktail and method of use |
JPH1077285A (ja) * | 1996-09-04 | 1998-03-24 | Sumitomo Pharmaceut Co Ltd | 新規なβ−ラクタム化合物およびその製造法 |
GB0028710D0 (en) * | 2000-11-24 | 2001-01-10 | Isis Innovation | Mixed fibrils |
CA2468033C (en) * | 2001-11-30 | 2008-02-12 | Lg Life Sciences Ltd. | A method of treating bacterial infections using gemifloxacin or a salt thereof and a carbapenem antibacterial agent |
-
2005
- 2005-09-09 US US11/664,810 patent/US20090018111A1/en not_active Abandoned
- 2005-09-09 JP JP2006540852A patent/JPWO2006040893A1/ja active Pending
- 2005-09-09 KR KR1020077009294A patent/KR20070061895A/ko not_active Application Discontinuation
- 2005-09-09 CN CN2005800344249A patent/CN101039669B/zh not_active Expired - Fee Related
- 2005-09-09 EP EP05782332A patent/EP1797879A4/en not_active Withdrawn
- 2005-09-09 CA CA002581663A patent/CA2581663A1/en not_active Abandoned
- 2005-09-09 WO PCT/JP2005/016611 patent/WO2006040893A1/ja active Application Filing
- 2005-09-16 TW TW094132199A patent/TW200621243A/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002525275A (ja) * | 1998-09-01 | 2002-08-13 | メルク エンド カムパニー インコーポレーテッド | カルバペネム抗菌組成物および治療方法 |
WO2002038564A1 (en) * | 2000-11-08 | 2002-05-16 | Sumitomo Pharmaceuticals Company, Limited | NOVEL β-LACTAM COMPOUNDS AND PROECSS FOR PRODUCING THE SAME |
Non-Patent Citations (4)
Title |
---|
See also references of EP1797879A4 |
SUNAGAWA M. ET AL: "New Anti-MRSA and Anti-VRE Carbapenems; Synthesis and Structure-activity Relationships of 1beta-Methyl-2-(thiazol-2-ylthio)carbapenems", THE JOURNAL OF ANTIBIOTICS, vol. 55, no. 8, August 2002 (2002-08-01), pages 722 - 757, XP002994367 * |
THE JAPANESE JOURNAL OF ANTIBIOTICS, vol. 58, 2005, pages 168 - 178 |
UEDA Y. AND SUNAGAWA M.: "In Vitro and in Vivo Activities of Novel 2-(Thiazol-2-ylthio)-1beta-Methylcarbapenems with Potent Activities against Multiresistant Gram-Positive Bacteria", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 47, no. 8, August 2003 (2003-08-01), pages 2471 - 2480, XP002986776 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009075323A1 (ja) * | 2007-12-12 | 2009-06-18 | Dainippon Sumitomo Pharma Co., Ltd. | β-ラクタム化合物の安定形結晶 |
Also Published As
Publication number | Publication date |
---|---|
KR20070061895A (ko) | 2007-06-14 |
CN101039669A (zh) | 2007-09-19 |
TW200621243A (en) | 2006-07-01 |
EP1797879A1 (en) | 2007-06-20 |
EP1797879A4 (en) | 2009-05-06 |
JPWO2006040893A1 (ja) | 2008-05-15 |
CN101039669B (zh) | 2010-06-16 |
CA2581663A1 (en) | 2006-04-20 |
US20090018111A1 (en) | 2009-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11433055B2 (en) | Chromane monobactam compounds for the treatment of bacterial infections | |
US20060106034A1 (en) | Drug efflux pump inhibitor | |
KR20170132316A (ko) | 헤테로고리 화합물 및 박테리아 감염의 예방 또는 치료에서 그들의 용도 | |
EP2900244B1 (en) | Tazobactam arginine antibiotic compositions | |
AU2016367284B2 (en) | Cephem compounds, their production and use | |
US6458780B1 (en) | Carbapenem derivatives | |
WO2006040893A1 (ja) | 新規な抗菌性医薬 | |
KR20180051559A (ko) | 베타-락타마제의 억제용 조성물 및 억제 방법 | |
EP1022279B1 (en) | New carbapenem derivatives | |
WO1996028455A1 (fr) | Nouveaux derives de carbapeneme | |
CS414991A3 (en) | Optically pure (5r, 6s, 1'r) configured 6-(1-hydroxyethyl)-2-methoxymethylpenem-3-carboxylic acid, process of its preparation and a pharmaceutical comprising said acid | |
US20110172200A1 (en) | Use of inhibitor of beta-lactamases and its combination with beta-lactam antibiotics | |
JP2010518142A (ja) | 三環式カルバペネムおよび抗生物質の抗菌的組み合わせ | |
EP0735871B1 (en) | Pharmaceutical compositions containing ceftriaxone and penems | |
US6680313B2 (en) | Carbapenum derivatives | |
MXPA99006526A (en) | New carbapenem derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006540852 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2581663 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005782332 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11664810 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580034424.9 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077009294 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2005782332 Country of ref document: EP |